Spotlight: Positive Phase 2 Results: Psilocybin-Assisted Psychotherapy Treatment, PSX-001, for Generalized Anxiety Disorder (2025)
"All participants received equal hours of psychological support and preparation, ensuring that any treatment effect could be attributed to psilocybin itself and not therapeutic bias."
In the randomized, double-blind, placebo-controlled phase 2 study, investigators enrolled 73 adult participants diagnosed with moderate to severe GAD. Participants were randomly assigned to complete 2 dosing sessions with either a 25 mg dose of synthetic psilocybin or placebo, which was administered in a controlled clinical setting as part of a proprietary psychotherapeutic protocol.
Positive Phase 2 Results: Psilocybin-Assisted Psychotherapy Treatment, PSX-001, for Generalized Anxiety Disorder
Incannex Healthcare shared positive data from its phase 2 clinical trial of PSX-001, a psilocybin-assisted psychotherapy treatment for generalized anxiety disorder.
Leah Kuntz